CMC Center
The CMC (Chemistry, Manufacturing, and Controls) Center focuses on the discovery and development of innovative drugs, and the research of drug formulation and drug delivery systems, including developing synthetic routes and formulation processes, as well as researching analytical methods and quality standards. Backed by in-house knowhow technology platforms and equipment compliant with the GMP standards, CMC-Small Molecules has established a full-process, well-developed, and standardized R&D system from laboratory to commercial.
Chemistry Development Platform
Pharmaceutical formulation Development Platform
Quality Research Platform
Chemistry Development Platform
Crystallization process, process optimization, separation and purification, and chemistry database.
Pharmaceutical formulation Development Platform
Preformulation studies, formulation studies, sustained and controlled release platform, low solubility drug platform, GastroPlus prediction (PBPK modeling), and more.
Quality Research Platform
Chromatographic quantitative analysis, physicochemical characterization, PEGylation characterization, genotoxic impurities study, and elemental impurities study Suggested updates: Chromatographic quantitative analysis, compound structure elucidation and identification, physicochemical characterization, PEGylation characterization, genotoxic impurities study, elemental impurities study, and more.
PROTAC Platform
PROTAC (proteolysis-targeting chimera) is a new protein degradation technology developed based on the utilization of ubiquitin-protease system. Hansoh Pharma has built a unique PROTAC platform for the development of highly selective and orally active efficacious targeted protein degradation drugs for oncology and autoimmune diseases.
siRNA Platform
siRNA generally refers to short interfering RNA or silencing RNA, which is a double-stranded RNA of 20 to 25 nucleotides in length and has many different uses in biology. At present, our Company has gradually developed few key technologies of siRNA chemical synthesis at highly advanced level, including RNA monomer synthesis technology, common and modified siRNA oligo synthesis technology.
Nanoformulation Platform
Nanoformulations refer to new type of drug formulations developed by applying nanotechnology, in which nanocarriers are used to bind with drugs or wrap drugs inside. At present, Hansoh Pharma has mastered the nanoformulation technology, which can meet the development needs of ongoing projects in terms of improving oral absorption of insoluble drugs, targeted release and macromolecular drug carriers.
PEGylation Long-acting Drug Platform
PEGylation is a mainstream long-acting modification technology for macromolecular drugs, which can effectively prolong the half-life of peptide and protein drugs in vivo, reduce immunogenicity, and improve efficacy and patient compliance. Hansoh Pharma has established a national-local joint engineering research center for the development of long-acting polypeptide biologics approved by the National Development and Reform Commission, which is a domestically leading and internationally advanced project.
